These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 9256229)

  • 21. Early and late clinical outcome following coronary angioplasty performed with platelet glycoprotein IIb/IIIa receptor inhibition: the EPIC Trial results.
    Popma JJ; Satler LF
    J Invasive Cardiol; 1994; 6 Suppl A():19A-28A; discussion 45A-50A. PubMed ID: 10155090
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The safety and efficacy of glycoprotein IIb/IIIa inhibitors for primary angioplasty: more options to choose and more time to decide.
    Moliterno DJ; Ziada KM
    J Am Coll Cardiol; 2008 Feb; 51(5):536-7. PubMed ID: 18237681
    [No Abstract]   [Full Text] [Related]  

  • 23. In the era of stabilize and seal, is there a role for GP IIb/IIIa agents in PCI?
    Gilchrist IC
    Catheter Cardiovasc Interv; 2010 May; 75(6):903-4. PubMed ID: 20432396
    [No Abstract]   [Full Text] [Related]  

  • 24. Glycoprotein IIb/IIIa receptor inhibitors in 2008: do they still have a role?
    Mukherjee D; Roffi M
    J Interv Cardiol; 2008 Apr; 21(2):118-21. PubMed ID: 18384343
    [No Abstract]   [Full Text] [Related]  

  • 25. Frequency and efficacy of glycoprotein IIb/IIIa therapy for treatment of threatened or acute vessel closure in 1332 patients undergoing percutaneous transluminal coronary angioplasty.
    Haase KK; Mahrholdt H; Schröder S; Baumbach A; Oberhoff M; Herdeg C; Karsch KR
    Am Heart J; 1999 Feb; 137(2):234-40. PubMed ID: 9924156
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Glycoprotein inhibitors and fibrinolysis in myocardial infarction.
    Ring BL
    JAMA; 2000 Dec; 284(24):3124-5. PubMed ID: 11135766
    [No Abstract]   [Full Text] [Related]  

  • 27. Glycoprotein IIb/IIIa inhibitors: current indications and future prospects.
    Reginelli JP; Topol EJ
    Am J Med; 2000 Aug; 109(3):252-4. PubMed ID: 10974193
    [No Abstract]   [Full Text] [Related]  

  • 28. Comparison of angioplasty with stenting in acute myocardial infarction.
    Herrmann HC
    N Engl J Med; 2002 Aug; 347(5):367-8; author reply 367-8. PubMed ID: 12151478
    [No Abstract]   [Full Text] [Related]  

  • 29. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators.
    Lincoff AM; Califf RM; Moliterno DJ; Ellis SG; Ducas J; Kramer JH; Kleiman NS; Cohen EA; Booth JE; Sapp SK; Cabot CF; Topol EJ
    N Engl J Med; 1999 Jul; 341(5):319-27. PubMed ID: 10423466
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Should glycoprotein IIb/IIIa inhibitors be used during all percutaneous coronary interventions? No.
    Ragosta M; Sarembock IJ
    J Thromb Haemost; 2004 Jan; 2(1):10-2. PubMed ID: 14717959
    [No Abstract]   [Full Text] [Related]  

  • 31. [Inhibitors of platelet glycoprotein IIb-IIIa in cardiology].
    Obradović S; Gligić B; Djordjević D; Jovicić A; Romanović R; Ratković N; Dincić D; Orozović V; Nikolić G
    Vojnosanit Pregl; 2001; 58(1):65-72. PubMed ID: 11419288
    [No Abstract]   [Full Text] [Related]  

  • 32. Should glycoprotein IIb/IIIa inhibitors be used during all percutaneous coronary interventions? Yes.
    Exaire JE; Lincoff AM
    J Thromb Haemost; 2004 Jan; 2(1):7-9. PubMed ID: 14717958
    [No Abstract]   [Full Text] [Related]  

  • 33. The benefits of platelet glycoprotein IIb/IIIa receptor inhibition during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: drug-specific or class effect?
    Brener SJ
    J Am Coll Cardiol; 2009 May; 53(18):1674-6. PubMed ID: 19406343
    [No Abstract]   [Full Text] [Related]  

  • 34. Mechanical reperfusion: treat well, treat on time too.
    Montalescot G
    Lancet; 2008 Aug; 372(9638):509-10. PubMed ID: 18707968
    [No Abstract]   [Full Text] [Related]  

  • 35. [Should treatment with glycoprotein IIa/IIIb receptor blocker be controlled in patients undergoing coronary intervention?].
    Heras M
    Rev Esp Cardiol; 2001 Nov; 54(11):1251-3. PubMed ID: 11707232
    [No Abstract]   [Full Text] [Related]  

  • 36. Letter by Lin et al regarding article, "Triple versus dual antiplatelet therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention".
    Lin GM; Chu KM; Han CL
    Circulation; 2010 Feb; 121(7):e43; author reply e44-5. PubMed ID: 20177003
    [No Abstract]   [Full Text] [Related]  

  • 37. [Monoclonal antibodies in cardiology].
    Legrand V
    Rev Med Liege; 2009; 64(5-6):310-2. PubMed ID: 19642465
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Theombolysis with GP IIb/IIIa-receptor blockader. Platelt aggregation inhibition: clear indications, new strategies].
    Internist (Berl); 1998 Dec; 39(12 Suppl Plattchena):1-4. PubMed ID: 10101692
    [No Abstract]   [Full Text] [Related]  

  • 39. Use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
    Parmar R; Stouffer GA
    Am J Med Sci; 1997 Jul; 314(1):31-6. PubMed ID: 9216438
    [No Abstract]   [Full Text] [Related]  

  • 40. Clopidogrel treatment prior to percutaneous coronary intervention: when enough isn't enough.
    Steinhubl SR; Charnigo R
    JAMA; 2006 Apr; 295(13):1581-2. PubMed ID: 16533936
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.